CKD-391 DDI : Atorvastatin and Ezetimibe in Healthy Volunteers

• Status: Completed
• Trial end date: 2015-02-01
• Target enrollment: 0
• Participant gender: All

Summary

A randomized open-label, multiple dose, three-treatment, three-period, six-sequence, crossover study to investigate the pharmacokinetic drug interaction between Atorvastatin and Ezetimibe after oral administration in healthy volunteers

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Chong Kun Dang Pharmaceutical
• Treatments: Atorvastatin; Atorvastatin Calcium; Calcium, Dietary; Ezetimibe

Criteria

Inclusion Criteria:

1. Age Eligible for Study : 19 Years to 45 Years

2. If males, Body weight ≥ 55kg, If females, Body weight ≥ 50kg

3. BSA ≥ 18.5, <25

4. Accepts healthy volunteers

5. If female, Negative for pregnancy test at the screening and pre dose of Day 1

6. The subjects who agree with performing contraception during the study

7. The subjects who agreed with written informed consent

Exclusion Criteria:

1. The subjects with impaired hepatic function, renal function, nervous system etc.

2. The subjects have a gastrointestinal disease or surgery which can be effected in absorption of Investigational product

3. The subjects with high blood pressure or low blood pressure (Systolic blood pressure>150mmHg or <90mmHg, Diastolic blood pressure>100mmHg or <50mmHg

4. The subjects with abnormal Laboratory test (AST, ALT>1.25 fold of upper normal limit, Total bilirubin>1.5 fold of upper normal limit, CPK>2 fold of upper normal limit, Estimated Glomerular filtration rate<60mL/min/1.73m2 by Modification of Diet in Renal disease formula

5. The subjects have drug abuse history within 1year or Positive for urine drug test at screening

6. The subjects who took prescription only medicine whch can be effected in metabolism of Investigational product within 14days

7. The subjects who took over the counter drug whch can be effected in metabolism of Investigational product within 7days